Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial

被引:6
作者
van Nes, J. G. H. [1 ]
Seynaeve, C. [2 ]
Maartense, E. [3 ]
Roumen, R. M. H. [4 ]
de Jong, R. S. [5 ]
Beex, L. V. A. M. [6 ]
Kranenbarg, W. M. Meershoek-Klein [7 ]
Putter, H. [8 ]
Nortier, J. W. R. [9 ]
van de Velde, C. J. H. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
[2] Daniel Denhoed Canc Ctr, Erasmus Med Ctr, Dept Med Oncol, Rotterdam, Netherlands
[3] Reinier Graaf Gasthuis, Dept Internal Med, Delft, Netherlands
[4] Maxima Med Ctr, Dept Surg, Veldhoven, Netherlands
[5] Martini Hosp, Dept Internal Med, Groningen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands
[7] Leiden Univ, Med Ctr, Datactr Surg, NL-2300 RC Leiden, Netherlands
[8] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands
[9] Leiden Univ, Med Ctr, Dept Med Oncol, NL-2300 RC Leiden, Netherlands
关键词
breast cancer; endocrine therapy; guideline; patterns of care; AROMATASE INHIBITORS; THERAPY; WOMEN; SURVIVAL; RECOMMENDATIONS; NETHERLANDS; MASTECTOMY; MANAGEMENT; LETROZOLE; SURGERY;
D O I
10.1093/annonc/mdp419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Methods: Clinicopathological characteristics, carried out local treatment strategies and adjuvant chemotherapy data were collected. Results: From 2001 to January 2006, 2754 Dutch patients were randomised to the study. Mean age of patients was 65 years (standard deviation 9). Tumours were < 2 cm in 46% (within CCCRs 39%-50%), node-negative disease varied from 25% to 45%, and PgR status was determined in 75%-100% of patients. Mastectomy was carried out in 55% (45%-70%), sentinel lymph node procedure in 68% (42%-79%) and axillary lymph node dissections in 77% (67%-83%) of patients, all different between CCCRs (P < 0.0001). Adjuvant chemotherapy was given in 15%-70% of eligible patients (P < 0.001). Discussion: In spite of national guidelines, breast cancer treatment on specific issues widely varied between the various Dutch regions. These data provide valuable information for breast cancer organisations indicating (lack of) guideline adherence and areas for breast cancer care improvement.
引用
收藏
页码:974 / 982
页数:9
相关论文
共 32 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Albain Kathy S, 2005, Clin Breast Cancer, V6, P412, DOI 10.3816/CBC.2005.n.045
  • [3] Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup trials
    Albain, KS
    Green, SR
    Lichter, AS
    Hutchins, LF
    Wood, WC
    Henderson, IC
    Ingle, JN
    OSullivan, J
    Osborne, CK
    Martino, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (11) : 3009 - 3017
  • [4] Factors associated with surgical and radiation therapy for early stage breast cancer in older women
    BallardBarbash, R
    Potosky, AL
    Harlan, LC
    Nayfield, SG
    Kessler, LG
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (11): : 716 - 726
  • [5] BARTLETT JMS, 2008, SAN ANT 2008 2009 31
  • [6] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
    Boccardo, F.
    Rubagotti, A.
    Guglielmini, P.
    Fini, A.
    Paladini, G.
    Mesiti, M.
    Rinaldini, M.
    Scali, S.
    Porpiglia, M.
    Benedetto, C.
    Restuccia, N.
    Buzzi, F.
    Franchi, R.
    Massidda, B.
    Distante, V.
    Amadori, D.
    Sismondi, P.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : VII10 - VII14
  • [7] Chang JH, 2001, CANCER-AM CANCER SOC, V91, P1231, DOI 10.1002/1097-0142(20010401)91:7<1231::AID-CNCR1123>3.0.CO
  • [8] 2-K
  • [9] Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
    Coombes, R. C.
    Kilburn, L. S.
    Snowdon, C. F.
    Paridaens, R.
    Coleman, R. E.
    Jones, S. E.
    Jassem, J.
    Van de Velde, C. J. H.
    Delozier, T.
    Alvarez, I.
    Del Mastro, L.
    Ortmann, O.
    Diedrich, K.
    Coates, A. S.
    Bajetta, E.
    Holmberg, S. B.
    Dodwell, D.
    Mickiewicz, E.
    Andersen, J.
    Lonning, P. E.
    Cocconi, G.
    Forbes, J.
    Castiglione, M.
    Stuart, N.
    Stewart, A.
    Fallowfield, L. J.
    Bertelli, G.
    Hall, E.
    Bogle, R. G.
    Carpentieri, M.
    Colajori, E.
    Subar, M.
    Ireland, E.
    Bliss, J. M.
    [J]. LANCET, 2007, 369 (9561) : 559 - 570
  • [10] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    Coombes, RC
    Hall, E
    Gibson, LJ
    Paridaens, R
    Jassem, J
    Delozier, T
    Jones, SE
    Alvarez, I
    Bertelli, G
    Ortmann, O
    Coates, AS
    Bajetta, E
    Dodwell, D
    Coleman, RE
    Fallowfield, LJ
    Mickiewicz, E
    Andersen, J
    Lonning, PE
    Cocconi, G
    Stewart, A
    Stuart, N
    Snowdon, CF
    Carpentieri, M
    Massimini, G
    Bliss, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1081 - 1092